NSE: ROSSARI | BSE: 543213

Mid-range Performer

Download real time

678.20 -8.45 (-1.23%)

30.28% Fall from 52W High

79,349 NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

3,754.8

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

24 Jan 2025

678.20

-1.23%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

•Rossari reported slightly lower-than-expected revenue but achieved 11% YoY growth, driven by strong execution in export markets for HPPC and textile segments, along with healthy performance in key ANH markets, despite challenging domestic conditions.
•Despite delivering lower than expected revenue, gross profit grew 16% YoY, aided by new product launches in Buzil Rossari Business.

Rossari Biotech Ltd. is trading below its 100 day SMA of 725.4

Rossari Biotech Ltd.

23 Oct 2024

678.20

-1.23%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech reported lower than expected topline and bottom line Q2FY25 due to softer HPPC growth and material weakness in TSC segment. Despite these pressures , it posted 3.1%/12%/3.2%/7.2% revenue /GP/EBITDA/PAT growth on YOY basis led by heathy export growth in the HPPC segment.

Rossari Biotech Ltd. is trading below its 100 day SMA of 725.4

Rossari Biotech Ltd.

22 Oct 2024

678.20

-1.23%

Rossari Biotech | Q2FY25 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. is trading above its 50 day SMA of 650.2

Rossari Biotech Ltd.

22 Oct 2024

678.20

-1.23%

HPPC steady; outlook bright backed by capex, market gain; Buy

Buy: Rossari Biotech Ltd.

Target

Anand Rathi

We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Rossari Biotech Ltd. has an average target of 939.75 from 4 brokers.

Rossari Biotech Ltd.

21 Oct 2024

678.20

-1.23%

Exports drive revenue growth

Hold: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY25 HPPC revenue growth (+6.2% YoY) was hurt from softer demand and restricted ethylene oxide (EO) capacity.

Rossari Biotech Ltd. has lost -20.65% in the last 6 Months

Rossari Biotech Ltd.

24 Jul 2024

678.20

-1.23%

Top-line to grow with the support of volume

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech’s revenue beat our estimate (+2.8%) due to strong volume growth in HPPC (Home, Personal Care, and Performance Chemicals) business and in the TSC (Textile Specialty Chemicals) division.
We anticipate this growth momentum in revenue will continue due to strong demand in the end customer segments.

Rossari Biotech Ltd. has lost -20.65% in the last 6 Months

Rossari Biotech Ltd.

13 Jun 2024, 12:00AM

678.20

-1.23%

Diversified business mix; no major China competition; initiating, with a Buy

Buy: Rossari Biotech Ltd.

Anand Rathi

Rossari Biotech is a leading specialty chemicals manufacturing company, focusing on four core chemistries of enzymes, silicones, acrylics and surfactants. It caters to industries such as home and personal care, and performance chemicals (HPPC), textile specialty chemicals (TSC) and animal health and nutrition (AHN) products

Rossari Biotech Ltd. is trading below its 100 day SMA of 725.4

Rossari Biotech Ltd.

08 May 2024

678.20

-1.23%

Strong growth in HPPC segment drives the performance

Buy: Rossari Biotech Ltd.

Target

KRChoksey

Rossari Biotech missed our revenue estimate due to subdued growth In Textile Specialty Chemical segment and Animal Health Nutrition segment which was partially offset by growth in Home, Personal care and Performance chemicals (HPPC) segment.
The stock is trading at PE multiples of 23.3x/18.9x based on FY25E/FY26E EPS estimates, respectively.

Rossari Biotech Ltd. has an average target of 939.75 from 4 brokers.

Rossari Biotech Ltd.

01 May 2024

678.20

-1.23%

Rossari Biotech | Q4FY24 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC and capex to drive growth

Rossari Biotech Ltd. has an average target of 939.75 from 4 brokers.

Rossari Biotech Ltd.

25 Jan 2024

678.20

-1.23%

Strong revenue growth with stable profitability

Buy: Rossari Biotech Ltd.

Recommendation Target

KRChoksey

For Q3FY24, Rossari Biotech's revenue was INR 4,638 Mn which grew by 19.1% YoY but declined by 4.1% QoQ. This growth was driven by strong growth in HPPC segment, which posted solid double-digit growth of 31.1% YoY but declined 3.2% QoQ to reach revenue of INR 3,554 Mn.

Rossari Biotech Ltd. is trading above its 50 day SMA of 650.2

VOTE: Is Rossari Biotech Ltd. worth buying?

66 Votes:

Buy 90.91%

Sell 3.03%

Hold 6.06%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf